Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection

References

• Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313–25.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011;34:604–17.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23–34.
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut 2012;61:646–64.
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Cristofari F, Iegri C, De Francesco V. How to manage Helicobacter pylori after sequential therapy failure? J Clin Gastroenterol 2010;44:459–60.
   PubMedGoogle Scholar
• Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori ‘test-and-treat' strategy on 736 patients in clinical practice. Helicobacter 2004;9:28–38.
   PubMedGoogle Scholar
• Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047–57.
   PubMed Web of Science ®Google Scholar
• Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319–28.
   PubMed Web of Science ®Google Scholar
• Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol 2001;1:7.
   PubMedGoogle Scholar
• de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000;320:31–4.
   PubMed Web of Science ®Google Scholar
• Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283–5.
   PubMedGoogle Scholar
• Watanabe Y, Aoyama N, Shirasaka D, Maekawa S, Kuroda K, Miki I, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711–15.
   PubMedGoogle Scholar
• Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45–9.
   PubMed Web of Science ®Google Scholar
• Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997–1002.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Miki I, Aoyama N, Shirasaka D, Watanabe Y, Morita Y, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821–5.
   PubMedGoogle Scholar
• Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract 2012;2012:974594.
   PubMedGoogle Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 Jan 1;23:35–44.
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488–96.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413–22.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Perez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, Barrio J, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013;47:130–5.
   Google Scholar
• Graham DY, Calvet X. Guide Regarding Choice of Second-line Therapy to Obtain a High Cumulative Cure Rate. Helicobacter 2012;17:243–5.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Pérez-Trallero E, Ramírez-Lázaro MJ, Villar H, Royo G, Montes M, Lario S, et al. Resistencia de Helicobacter pylori a diversos antibióticos: un estudio multicéntrico Español. Gastroenterol Hepatol 2011;34:236.
   Google Scholar
• Manfredi M, Bizzarri B, De'angelis GL. Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate. Helicobacter 2012;17:246–53.
   PubMed Web of Science ®Google Scholar
• Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001–5.
   PubMedGoogle Scholar
• Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis 2010;42:541–3.
   PubMedGoogle Scholar
• Zullo A, De Francesco V, Hassan C. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 2006;3:251–4.
   Google Scholar
• Chung HK, Ho Lee D, Kim N, Min Shin C, Hyeok Hwang J, Hyub Lee S, et al. Efficacy of Second-Line Treatment for Helicobacter pylori Infection: Moxifloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy. Gastroenterology 2012;142:S-483–4.
   Web of Science ®Google Scholar
• Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 2007;12:645–7.
   PubMedGoogle Scholar
• Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003;17:1137–43.
   PubMed Web of Science ®Google Scholar
• Buzas GM, Jozan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2007;22:1571–81.
   PubMed Web of Science ®Google Scholar
• Fakheri H, Bari Z, Sardarian H. A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure. Helicobacter 2012;17:264–8.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for Helicobacter pylori: is it effective and safe? World J Gastroenterol 2009;15:1914–15.
   PubMedGoogle Scholar
• Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol 2012;18:1–2.
   PubMed Web of Science ®Google Scholar